View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Progress on share buyback programme

Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €2.0 billion share buyback programme announced on 31 October 2024, in total 5,545,654 shares were repurchased during the week of 11 November 2024 up to and including 15 November 2024. The shares were repurchased at an average price of €14.88 or a total amount of €82,507,552.62. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see the ING website at . In line with the purpose of the programme to reduce the sha...

 PRESS RELEASE

Progress on share buyback programme

Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €2.0 billion share buyback programme announced on 31 October 2024, in total 7,704,055 shares were repurchased during the week of 4 November 2024 up to and including 8 November 2024. The shares were repurchased at an average price of €15.35 or a total amount of €118,240,205.76. For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see . In line with the purpose of the programme to reduce the share capital of ING, t...

Jørgen Lian
  • Jørgen Lian

CMB.TECH (Hold, TP: USD14.10) - Diversification at a cost

CMB.TECH’s diversified and ‘future-proof’ approach may prove attractive in steadily managing shipping cycles, changing fundamentals and stricter environmental regulations. However, diversification also comes at a price, and its heavy newbuild programme is straining its balance sheet and the outlook for dividends. Thus, we currently see greater upside potential in its pure crude tanker peers. We reiterate our HOLD and have lowered our target price to USD14.1 (16.3).

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: Building already bottoming, industry tough. Air France-KLM: Nobody helps. Alfen: Covenant agreement, hikes output Smart Grid. AMG: Sweet for 2024F, sour for 2025F. ArcelorMittal: 3Q24 EBITDA beats by 6%, FCF solid. BAM: 3Q beats, on its way to reach FY guidance. CMB.TECH: 3Q and FY24 reasonable but then more challenges. D'Ieteren: EGM and dividend dates announced; Belron US peer Boyd disappointing 3Q24. GBL: Double-digit TSR expected over 2024-27F. KBC: 3Q better acro...

Hilde Van Boxstael ... (+8)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste

Morning Notes : AALB NA, ADYEN NA, CPINV BB, CMBT BB, GBLB BB, MDXH BB...

: AALB NA, ADYEN NA, CPINV BB, CMBT BB, GBLB BB, MDXH BB, TESB BB, ALFEN NA

Jacob Mekhael
  • Jacob Mekhael

ASH abstracts Autolus, Galapagos, MaaT

The abstracts for presentations at ASH (7-10 December) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (digging deeper into the obe-cel dataset), Galapagos (more CAR-T data and pre-clinical data on TCR-T) and MaaT (early access program in aGvHD):

 PRESS RELEASE

Galapagos to Present Results of Pioneering Innovation in Cancer Cell T...

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our cutting-e...

 PRESS RELEASE

Galapagos presenteert resultaten van baanbrekende innovatie in kankerc...

Galapagos presenteert resultaten van baanbrekende innovatie in kankerceltherapie op ASH 2024 Nieuwe fase 1/2 resultaten ondersteunen het potentieel van onze CAR T-celtherapiekandidaten, GLPG5101 en GLPG5201, om tegemoet te komen aan de onvervulde behoeften bij patiënten met een slechte prognose. Ons innovatieve gedecentraliseerde celtherapieproductieplatform levert verse, fitte cellen binnen een mediane vein-to-vein tijd van zeven dagen, met een bemoedigende impact op de resultaten voor patiënten. Drie abstracts, waaronder een mondelinge presentatie voor GLPG5101 bij recidief/refractair non...

 PRESS RELEASE

Progress on share buyback programme

Progress on share buyback programme Progress on share buyback programme ING announced today that, as part of our €2.0 billion share buyback programme announced on 31 October 2024, in total 4,016,274 shares were repurchased during the week of 31 October 2024 up to and including 1 November 2024. In line with the purpose of the programme to reduce the share capital of ING, the ordinary shares were repurchased at an average price of €15.64 for a total consideration of €62,798,086.93. To date approximately 3.14% of the maximum total value of the share buyback programme has been completed. F...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ageas: More bidders for ESURE UK ASR: Completion of KNAB sale, starting extra SBB D'Ieteren: Holding financing more costly, 2024 guidance (excluding financing) reassures Ebusco: Released from obligation to deliver 76 buses PostNL: 3Q24 below, FY24 outlook down, mail weak, parcels stronger; CEO steps down Sif Group: Preview - getting ready for 2025 Staffing: US temp volume weaker in October, Aug/Sep revised down, NFP jobs miss

Cor Kluis
  • Cor Kluis

ING Group : Q3 Net interest income less by treasury volatility and Oth...

>3Q24 NII less by treasury volatility and Other income better - The 3Q24 underlying net interest income (NII) was below our expectations by volatile Treasury results. We reduced our estimated underlying NII for FY24 and FY25 somewhat. The Q3 expenses were in line with expectations and will continue to grow mid-single digit in 2025. End Q3 the pro forma CET1 ratio was 13.5% in line with our expectations, and with one year of SBB’s they can bring their CET1 ratio down t...

Jacob Mekhael
  • Jacob Mekhael

Galapagos 9M24 conference call feedback

Galapagos hosted a conference call to discuss its 9M24 results. Most noteworthy is that we learned of an R&D day panned for 2025, as well as the deal structure with the company's CAR-T manufacturing partners in the US. We summarise the main takeaways below.

Cor Kluis
  • Cor Kluis

ING Group : Net interest income less than expected by treasury in Q3, ...

>Conclusion: Q3 NII less than expected by treasury, rest in line - For Q3 the net interest income was less than expected by adverse treasury results, so that the consensus has to reduce their underlying FY24 NII somewhat. The other recurring P&L items were in line with expectations like commission income and expenses. No change in our view on ING Group, Neutral.Q3 net interest income below expectations, NII consensus FY24 too high - In 3Q24 net intere...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch